RetinalGenix Technologies Inc.
RTGN · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.49 | -0.54 | -0.11 |
| FCF Yield | -2.58% | -0.65% | -0.14% | -2.72% |
| EV / EBITDA | -6.66 | -25.93 | -35.90 | 0.00 |
| Quality | ||||
| ROIC | 307.02% | 232.12% | 183.91% | 555.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.17 | 0.17 | 0.05 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -112.96% | -74.55% | 82.90% | 17.95% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -0.24 | -0.01 | 0.00 |
| Interest Coverage | -1,124.22 | -543.50 | -364.97 | -831.11 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -352,788.57 | -3,229,958.00 | -3,402,945.10 | 0.00 |